You are here

IPOs

Biopharma’s top 5 IPOs of 2023 (so far)

Biopharma’s top 5 IPOs of 2023 (so far)

Pharma Voice

Apogee Therapeutics

Neumora Therapeutics

Mineralys Therapeutics

Flag link:

Playing in the Hot Obesity Market, Carmot Braves Chilly IPO Waters

Playing in the Hot Obesity Market, Carmot Braves Chilly IPO Waters

BioSpace

Carmot Therapeutics

Flag link:

WuXi Biologics bioconjugates spinout plans $470 million IPO

WuXi Biologics bioconjugates spinout plans $470 million IPO

Biopharma Reporter

Flag link:

IPO Update: Cargo Therapeutics Readies Plans For $300 Million IPO

IPO Update: Cargo Therapeutics Readies Plans For $300 Million IPO

Seeking Alpha

Cargo Therapeutics

large B cell lymphoma

Flag link:

WuXi Biologics' medical research unit eyes up to $471 million in Hong Kong IPO

WuXi Biologics' medical research unit eyes up to $471 million in Hong Kong IPO

Reuters

Flag link:

Lexeo drops share price at last minute in attempt to raise $100M IPO

Lexeo drops share price at last minute in attempt to raise $100M IPO

Fierce Biotech

Lexeo Therapeutics

Flag link:

Lessons from a biotech downturn: Funding challenges, an IPO dry spell and what to expect in 2024

Lessons from a biotech downturn: Funding challenges, an IPO dry spell and what to expect in 2024

BioPharma Dive

Flag link:

5 financial challenges facing the medtech sector

5 financial challenges facing the medtech sector

Medtech Dive

Flag link:

How biotech IPOs performed in the third quarter

How biotech IPOs performed in the third quarter

BioPharma Dive

Neumora Therapeutics

Mira Pharmaceuticals

Turnstone Biologics

Apogee Therapeutics

Sagimet Biosciences

60 Degrees Pharma

Flag link:

Lexeo, Abivax File for IPOs on Nasdaq Amid Industry-Wide Drought

Lexeo, Abivax File for IPOs on Nasdaq Amid Industry-Wide Drought

BioSpace

Lexeo Therapeutics

genetic medicine

Flag link:

Adlai Nortye IPO gives old Novartis cancer drug new life

Adlai Nortye IPO gives old Novartis cancer drug new life

BioPharma Dive

head and neck cancer

Flag link:

Neumora Therapeutics stock surges as Amgen confirmed as major shareholder

Neumora Therapeutics stock surges as Amgen confirmed as major shareholder

Proactive Investors

Flag link:

Emcure Pharma plans to launch $400-500 million IPO in 2024

Emcure Pharma plans to launch $400-500 million IPO in 2024

Mint

Emcure Pharmaceuticals

Flag link:

Antibody biotech Abpro taps SPAC to get back on Nasdaq track 5 years after axed IPO

Antibody biotech Abpro taps SPAC to get back on Nasdaq track 5 years after axed IPO

Fierce Biotech

Flag link:

Biotech Financing, IPO Tide May Be Turning – Signs of a Potential Recovery?

Biotech Financing, IPO Tide May Be Turning – Signs of a Potential Recovery?

BioSpace

Neumora Therapeutics

Rome Therapeutics

Generate Biomedicines

Flag link:

RayzeBio, Neumora price some of biotech’s largest IPOs this year

RayzeBio, Neumora price some of biotech’s largest IPOs this year

BioPharma Dive

Neumora Therapeutics

Flag link:

SoftBank-backed Neumora Therapeutics aims to raise up to $264.8 mln in US IPO

SoftBank-backed Neumora Therapeutics aims to raise up to $264.8 mln in US IPO

NASDAQ

Neumora Therapeuticsl

Flag link:

Neumora, a richly funded brain drug developer, readies for an IPO

Neumora, a richly funded brain drug developer, readies for an IPO

BioPharma Dive

Neumora Therapeutics

Flag link:

RayzeBio plans IPO to push radiotherapy 'pipeline-in-a-product' through phase 3

RayzeBio plans IPO to push radiotherapy 'pipeline-in-a-product' through phase 3

Fierce Biotech

Flag link:

In a year with few biotech IPOs, ‘crossover’ financings are hard to find

In a year with few biotech IPOs, ‘crossover’ financings are hard to find

BioPharma Dive

crossover financing

Flag link:

Pages